22 results
SC14D9C
EX-2.1
PNT
POINT Biopharma Global Inc.
3 Oct 23
Written communication relating to third party tender offer
7:37am
, standards for the manufacture, processing, packaging, testing, transportation, handling and holding of drug products, as set forth in the FDCA
8-K
EX-2.1
PNT
POINT Biopharma Global Inc.
3 Oct 23
Tender and Support Agreement
7:35am
, standards for the manufacture, processing, packaging, testing, transportation, handling and holding of drug products, as set forth in the FDCA
ARS
2022 FY
PNT
POINT Biopharma Global Inc.
1 May 23
Annual report to shareholders
1:52pm
, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping … must develop methods for testing the identity, strength, quality and purity of the final product. Additionally, appropriate packaging must be selected
424B3
jij9gga83z8
31 Mar 22
Prospectus supplement
11:42am
POS AM
zt6s0 u3c0a
25 Mar 22
Prospectus update (post-effective amendment)
8:41am
424B3
EX-10.1
78x6nnmr
12 Nov 21
Prospectus supplement
8:41am
424B3
5nhx 5g3ck
5 Aug 21
Prospectus supplement
4:26pm
424B3
qvew8rt462fpmn10
9 Jun 21
Prospectus supplement
4:42pm
S-4/A
EX-10.14
dpotpqp
30 Apr 21
Registration of securities issued in business combination transactions (amended)
9:53pm
S-4/A
EX-10.19
dgcubywviwmzp4xys
30 Apr 21
Registration of securities issued in business combination transactions (amended)
9:53pm
S-4/A
gn9wi7 35e200od5eu
30 Apr 21
Registration of securities issued in business combination transactions (amended)
9:53pm
S-4
EX-10.14
2mzen521 h8q
22 Mar 21
Registration of securities issued in business combination transactions
9:52pm